Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice

• Main Authors: Fengfeng Li (Author), Man Jiang (Author), Minghui Ma (Author), Xuyang Chen (Author), Yidan Zhang (Author), Yixin Zhang (Author), Yuanyuan Yu (Author), Yunfeng Cui (Author), Jiahui Chen (Author), Hui Zhao (Author), Zhijie Sun (Author), Deli Dong (Author)
• Format: Book
• Published: Elsevier, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lipid metabolism disorders contribute to hyperlipidemia and hepatic steatosis. It is ideal to develop drugs simultaneous improving both hyperlipidemia and hepatic steatosis. Nitazoxanide is an FDA-approved oral antiprotozoal drug with excellent pharmacokinetic and safety profile. We found that nitaz...